T cell immunoglobulin and mucin-domain containing-3 (Tim-3) and its ligand, galectin-9 (Gal-9), have been gaining increasing attention as potential targets for cancer and infectious disease immunotherapy [150]. This evidence concerns the gene LGALS9 and cancer.